Literature DB >> 27899297

Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.

Andrea Notarpaolo1, Richard Layese2, Paolo Magistri3, Maria Gambato4, Michele Colledan5, Giulia Magini5, Lucia Miglioresi6, Alessandro Vitale7, Giovanni Vennarecci8, Cecilia D Ambrosio6, Patrizia Burra4, Fabrizio Di Benedetto3, Stefano Fagiuoli5, Marco Colasanti8, Giuseppe Maria Ettorre8, Arnoldo Andreoli6, Umberto Cillo7, Alexis Laurent9, Sandrine Katsahian2, Etienne Audureau2, Françoise Roudot-Thoraval2, Christophe Duvoux10.   

Abstract

BACKGROUND & AIMS: The AFP model was shown to be superior to the Milan criteria for predicting hepatocellular carcinoma (HCC) recurrence after liver transplantation in a French population. Our aim was to test the AFP model in a non-French, post-hepatitic cirrhosis-based population of HCC candidates.
METHODS: 574 patients transplanted for HCC in four Italian centers were studied. AFP score was assessed at the last evaluation before liver transplantation (LT). Probabilities of recurrence and survival were estimated by the log-rank test or competing risk analysis and compared according to the AFP model.
RESULTS: 24.7% patients were beyond Milan criteria. HCC complicated hepatitis C virus (HCV) and hepatitis B virus (HBV) cirrhosis in 58.7% and 24% of the cases, respectively. Five-year probabilities of recurrence differed according to AFP score ⩽2 vs. >2 in the whole population (13.2±1.8% vs. 49.8±8.7%, p<0.001, HR=4.98), in patients within Milan criteria (12.8±2.0% vs. 32.4±12.1%, p=0.009, HR=3.51), beyond Milan criteria (14.9±4.2% vs. 58.9±11.5%, p<0.001, HR=4.26), HCV patients (14.9±2.5% vs. 67.6±14.7%, p<0.001, HR=6.56) and HBV patients (11.6±3.4% vs. 34.3±12.5%, p=0.012, HR=3.49). By net reclassification improvement analysis AFP score significantly improved prediction of non-recurrence compared to Milan criteria. Overall five-year survival rates according to AFP score ⩽2 or >2 were 71.7±2.2% vs. 42.2±8.3% (p<0.001, HR=2.14).
CONCLUSIONS: The AFP model identifies HCC candidates at low risk of recurrence, otherwise excluded by Milan criteria in a population with a predominance of post-hepatitic-related HCC. The AFP score can be proposed for selection of HCC candidates in programs with a high proportion of viral/HCV-related cirrhosis. LAY
SUMMARY: Selection criteria for liver transplantation of patients affected with hepatocellular carcinoma (HCC) are based on the Milan criteria, which have been shown to be too restrictive, precluding access to liver transplantation for some patients who might be cured by this operation. Recently, a French group of researchers developed a new selection model called the AFP model, or AFP score, allowing some patients with HCC not meeting Milan criteria to be transplanted with excellent results. In the present work, the AFP score was tested in a population of non-French patients transplanted for HCC occurring mainly on post-hepatitic (HCV or HBV) cirrhosis. The results confirm that in this specific population, as in the original French population of patients, the AFP model better selects patients with HCC eligible for transplantation, compared to Milan criteria. We conclude that the AFP score, which has been officially adopted by the French organization for Organ Sharing for HCC patients, can also be implemented in countries with an important burden of HCC occurring on post-hepatitic cirrhosis.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AFP; AFP model; AFP score; Alfa fetoprotein; Hepatitis; Hepatocellular carcinoma; Liver cirrhosis; Liver transplantation; Predictive model; Validation

Mesh:

Substances:

Year:  2016        PMID: 27899297     DOI: 10.1016/j.jhep.2016.10.038

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  48 in total

1.  Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.

Authors:  Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2020-10       Impact factor: 2.485

Review 2.  Role of inflammatory markers as hepatocellular cancer selection tool in the setting of liver transplantation.

Authors:  Russell E Rosenblatt; Zaid H Tafesh; Karim J Halazun
Journal:  Transl Gastroenterol Hepatol       Date:  2017-11-21

Review 3.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

4.  Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre.

Authors:  Friedrich Foerster; Maria Hoppe-Lotichius; Johanna Vollmar; Jens U Marquardt; Arndt Weinmann; Marcus-Alexander Wörns; Gerd Otto; Tim Zimmermann; Peter R Galle
Journal:  United European Gastroenterol J       Date:  2019-03-25       Impact factor: 4.623

5.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

6.  Preoperative alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC): is this 50-year biomarker still up-to-date?

Authors:  Fabrice Muscari; Charlotte Maulat
Journal:  Transl Gastroenterol Hepatol       Date:  2020-10-05

Review 7.  Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?

Authors:  Nicole E Rich; Amit G Singal
Journal:  Hepatology       Date:  2022-01-18       Impact factor: 17.425

8.  Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.

Authors:  Arno Kornberg; Martina Schernhammer; Jennifer Kornberg; Helmut Friess; Katharina Thrum
Journal:  Dig Dis Sci       Date:  2018-09-27       Impact factor: 3.199

9.  Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model.

Authors:  Bleuenn Brusset; Jerome Dumortier; Daniel Cherqui; Georges-Philippe Pageaux; Emmanuel Boleslawski; Ludivine Chapron; Jean-Louis Quesada; Sylvie Radenne; Didier Samuel; Francis Navarro; Sebastien Dharancy; Thomas Decaens
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

10.  Clinical Value and Underlying Mechanisms of Upregulated LINC00485 in Hepatocellular Carcinoma.

Authors:  Xinyu Zhu; Yanlin Feng; Dingdong He; Zi Wang; Fangfang Huang; Jiancheng Tu
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.